SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ruihong Wu, Xiumei Chi, Xiaomei Wang, Haibo Sun, Juan Lv, Xiuzhu Gao, Ge Yu, Fei Kong, Hongqin Xu, Rui Hua, Jing Jiang, Bing Sun, Jin Zhong, Yu Pan, Junqi Niu, IFNL4 ss469415590 polymorphism contributes to treatment decisions in patients with chronic hepatitis C virus genotype 1b, but not 2a, infection, Infection, Genetics and Evolution, 2016, 39, 132

    CrossRef

  2. 2
    Kai-Henrik Peiffer, Lisa Sommer, Simone Susser, Johannes Vermehren, Eva Herrmann, Matthias Döring, Julia Dietz, Dany Perner, Caterina Berkowski, Stefan Zeuzem, Christoph Sarrazin, Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3, Hepatology, 2016, 63, 1
  3. 3
    E Cariani, L Roli, G Missale, E Villa, C Ferrari, T Trenti, Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis, The Pharmacogenomics Journal, 2016, 16, 1, 18

    CrossRef

  4. 4
    Maria Buti, Rafael Esteban, Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’, Expert Review of Gastroenterology & Hepatology, 2015, 9, 3, 375

    CrossRef

  5. 5
    C.-H. Liu, C.-J. Liu, C.-F. Huang, J.-W. Lin, C.-Y. Dai, C.-C. Liang, J.-F. Huang, P.-H. Hung, H.-B. Tsai, M.-K. Tsai, C.-Y. Lee, S.-I. Chen, S.-S. Yang, T.-H. Su, H.-C. Yang, P.-J. Chen, D.-S. Chen, W.-L. Chuang, M.-L. Yu, J.-H. Kao, Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial, Gut, 2015, 64, 2, 303

    CrossRef

  6. 6
    Chen-Hua Liu, Wang-Hui Sheng, Hsin-Yun Sun, Szu-Min Hsieh, Yi-Chun Lo, Chun-Jen Liu, Tung-Hung Su, Hung-Chih Yang, Wen-Chun Liu, Pei-Jer Chen, Ding-Shinn Chen, Chien-Ching Hung, Jia-Horng Kao, Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study, Scientific Reports, 2015, 5, 17410

    CrossRef

  7. 7
    Sreedhar Chinnaswamy, Genetic Variants at theIFNL3Locus and Their Association with Hepatitis C Virus Infections Reveal Novel Insights into Host-Virus Interactions, Journal of Interferon & Cytokine Research, 2014, 34, 7, 479

    CrossRef

  8. 8
    Mohammed Eslam, Reynold Leung, Manuel Romero-Gomez, Alessandra Mangia, William L. Irving, David Sheridan, Ulrich Spengler, Lindsay Mollison, Wendy Cheng, Elisabetta Bugianesi, Duncan McLeod, Abed M. Zaitoun, Vito Attino, Diane Goeltz, Jacob Nattermann, Mark Douglas, David R. Booth, Jacob George, Golo Ahlenstiel, IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection, Journal of Hepatology, 2014, 61, 2, 235

    CrossRef

  9. 9
    Ching-I Huang, Chung-Feng Huang, Jee-Fu Huang, Chia-Yen Dai, Ming-Lun Yeh, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Liang-Yen Wang, Ming-Lung Yu, Wan-Long Chuang, Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection, Journal of Gastroenterology and Hepatology, 2014, 29, 5
  10. 10
    Leo Swadling, Paul Klenerman, Eleanor Barnes, Ever closer to a prophylactic vaccine for HCV, Expert Opinion on Biological Therapy, 2013, 13, 8, 1109

    CrossRef

  11. 11
    Chen-Hua Liu, Jia-Horng Kao, IL28B Genotype on HCV Infection in Asia, Current Hepatitis Reports, 2013, 12, 3, 149

    CrossRef

  12. 12
    G. Grammatikos, C. Sarrazin, IL28B und antivirale Therapie der Virushepatitis: Was bleibt?, Der Gastroenterologe, 2013, 8, 4, 322

    CrossRef

  13. 13
    María A Jiménez-Sousa, Amanda Fernández-Rodríguez, María Guzmán-Fulgencio, Mónica García-Álvarez, Salvador Resino, Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C, BMC Medicine, 2013, 11, 1, 6

    CrossRef

  14. You have free access to this content14
    Mitchell L. Shiffman, Yves Benhamou, Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?, Liver International, 2013, 33,
  15. 15
    R López-Rodríguez, Á Hernández-Bartolomé, M J Borque, Y Rodríguez-Muñoz, S Martín-Vílchez, M Trapero-Marugán, L García-Buey, P Muñoz de Rueda, L Rodrigo, J R Vidal-Castiñeira, J Salmerón, R Moreno-Otero, P Sanz-Cameno, Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy, Genes and Immunity, 2013, 14, 5, 317

    CrossRef

  16. 16
    Chung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu, The Evolution of HCV Treatment in Taiwan, Current Hepatitis Reports, 2013, 12, 3, 143

    CrossRef

  17. 17
    Paul M. Trembling, Sudeep Tanwar, William M. Rosenberg, Geoffrey M. Dusheiko, Treatment decisions and contemporary versus pending treatments for hepatitis C, Nature Reviews Gastroenterology & Hepatology, 2013, 10, 12, 713

    CrossRef

  18. 18
    Heidar Sharafi, Ali Pouryasin, Seyed Moayed Alavian, Bita Behnava, Maryam Keshvari, Shima Salimi, Leila Mehrnoush, Ahmad Fatemi, Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals, Hepatitis Monthly, 2012, 12, 12

    CrossRef

  19. 19
    David R Booth, Golo Ahlenstiel, Jacob George, Pharmacogenomics of hepatitis C infections: personalizing therapy, Genome Medicine, 2012, 4, 12, 99

    CrossRef